Exclusive: OpenAI has acquired Orchestra Bio
Axiosen
OpenAI has acquired Orchestra Bio, a startup building AI agents to help pharmaceutical companies manage drug development, the ChatGPT maker shared exclusively with Axios. Why it matters: Rival AI giants OpenAI and Anthropic are both pushing into science as they look to expand beyond their core competencies in coding and cybersecurity. State of play: OpenAI will integrate Orchestra's team and technology into Rosalind, its suite of AI models and tools designed for life sciences researchers, the company said. Orchestra's platform allows scientists to delegate tasks like monitoring studies, tracking drug development timelines and identifying potential delays to AI agents. Both companies aim to d
This is a short summary published by AI Global Wire. The full article is owned and hosted by Axios — open it there to read it in full.
Read the full story at Axios- OpenAI
- Anthropic
- Verktyg
- Forskning
Related AI news
- Deepseek open-sources the inference engine that powers its fastest and cheapest AI modelThe Decoder · October 20, 2026
- Dell’s security chief warns AI is lowering the barriers to sophisticated cyberattacksSiliconANGLE · October 20, 2026
- Google has joined Amazon in attacking Nvidia’s stronghold with AI app developersTechCrunch AI · October 20, 2026
- ChatGPT now lets you lock your chatsTechCrunch AI · October 20, 2026
- A US judge dismisses a civil sexual abuse lawsuit brought against Sam Altman by his sister, after she refused to appear for an independent medical examination (Luc Cohen/Reuters)Techmeme · October 20, 2026
- OpenAI acquires Orchestra Bio, which builds AI agents for managing drug development, and plans to integrate its tech into OpenAI life sciences suite Rosalind (Madison Mills/Axios)Techmeme · October 20, 2026